Format

Send to

Choose Destination
Neurobiol Dis. 2016 Nov;95:210-24. doi: 10.1016/j.nbd.2016.07.022. Epub 2016 Jul 25.

Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases.

Author information

1
CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
2
CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal. Electronic address: ccavadas@uc.pt.

Abstract

Neuropeptide Y (NPY) and NPY receptors are widely expressed in the mammalian central nervous system. Studies in both humans and rodent models revealed that brain NPY levels are altered in some neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and Machado-Joseph disease. In this review, we will focus on the roles of NPY in the pathological mechanisms of these disorders, highlighting NPY as a neuroprotective agent, as a neural stem cell proliferative agent, as an agent that increases trophic support, as a stimulator of autophagy and as an inhibitor of excitotoxicity and neuroinflammation. Moreover, the effect of NPY in some clinical manifestations commonly observed in Alzheimer's disease, Parkinson's disease, Huntington's disease and Machado-Joseph disease, such as depressive symptoms and body weight loss, are also discussed. In conclusion, this review highlights NPY system as a potential therapeutic target in neurodegenerative diseases.

KEYWORDS:

Alzheimer's disease; Autophagy; Excitotoxicity; Huntington's disease; Machado-Joseph disease; NPY; NPY receptors; Neurodegenerative diseases; Neurogenesis; Neuroinflammation; Neuropeptide Y; Neuroprotection; Parkinson's disease; Trophic factors

PMID:
27461050
DOI:
10.1016/j.nbd.2016.07.022
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center